🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder

RecruitingNAAges 18 Years - anyAllBruyère Health Research Institute.
NCT06953596 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Grief is a normal response after the death of a loved one. With time, the grief response decreases and people learn to cope with their loss. However, for some, the response becomes more intense and distressing. This is called prolonged grief disorder (PGD). People with PGD experience emotional pain and a deep longing for their loved one. PGD normally occurs \<10% of people after a loss, but it has become more common since the COVID-19 pandemic (\~30%). If left untreated, PGD leads to poor quality of life and increased risk of death. Treatment options such as medication and therapy are available; however, they can cause negative side effects and take a long time to work. To help individuals with PGD, we need treatments that work well and quickly. Repetitive transcranial magnetic stimulation (rTMS) is a safe, non-invasive treatment that delivers magnetic pulses to brain areas responsible

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Bereaved individuals \>/= 18 years of age 2. Score \>25 on the Inventory of Complicated Grief 3. Must have a primary care physician 4. Ability to understand and communicate in English 5. Ability to provide first-person informed consent Exclusion Criteria: 1. Current or previously diagnosed seizure disorder 2. Documented brain lesions 3. Contraindications to TMS (i.e., metallic skull plates, clips, stimulators, pacemakers) 4. Current substance abuse disorder (e.g., schizophrenia) 5. Pregnancy or lactation, or trying to conceive 6. Advanced, incurable illness with an expected prognosis of \<3 months - bereaved family members are known to be at elevated risk of death from medical illness, but if death is expected in the near future, it would be difficult to justify using an entire week of their limited time for an unproven therapy.
💊

What it tests

  • Repetitive Transcranial Magnetic Stimulation (rTMS)
📍

Where

1 site
Bruyere Health
Ottawa, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy